Combined Let-7a and H19 Signature: A Prognostic Index of Progression-Free Survival in Primary Breast Cancer Patients.
10.4048/jbc.2018.21.2.142
- Author:
Qiannan GUO
1
;
Runyao WEN
;
Bin SHAO
;
Yudong LI
;
Xin JIN
;
Heran DENG
;
Jiannan WU
;
Fengxi SU
;
Fengyan YU
Author Information
1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangzhou, China. fengyanyu_summer@163.com
- Publication Type:Original Article
- Keywords:
Breast neoplasms;
H19 long non-coding RNA;
Hsa-let-7a-1 microRNA;
Neoadjuvant therapy;
Prognosis
- MeSH:
Breast Neoplasms*;
Breast*;
Cell Line;
Disease-Free Survival*;
Drug Therapy;
Humans;
In Vitro Techniques;
Methods;
Neoadjuvant Therapy;
Paclitaxel;
Porifera;
Prognosis;
Retrospective Studies;
RNA, Long Noncoding
- From:Journal of Breast Cancer
2018;21(2):142-149
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The long non-coding RNA H19, a conservatively imprinted gene, acts as a molecular sponge for the let-7 family, which has been identified as a set of tumor suppressors. However, the combined prognostic value of H19 and let-7a signature in breast cancer patients remains unclear. METHODS: In this research we assessed the prognostic value of the combined H19 and let-7a signature in breast cancer patients by retrospectively reviewing that data of 79 patients who underwent neoadjuvant chemotherapy; we also investigated the expression and function of H19 in breast cancer cell lines in vitro. Survival data were calculated using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate survival analyses were conducted using the Cox proportional hazards regression method. As determined using X-tile, the optimal cutoff value for the risk score to assess progression-free survival (PFS) based on the combined signature was –0.1. RESULTS: Patients with an overall positive treatment response had higher let-7a and lower H19 levels. In addition, let-7a expression was negatively correlated with H19 expression. Patients with a risk score of >–0.1 had shorter overall survival and PFS. In vitro data showed that chemoresistant cell lines exhibit higher H19 and lower let-7a levels and knockdown H19 restores paclitaxel sensitivity. CONCLUSION: Our results suggest that the combined let-7a and H19 signature is a novel prognostic factor for breast cancer patients treated with neoadjuvant chemotherapy.
